Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

0Tip RSCInsights

Authors

Cosette Wheeler•Fred Aoki27 more•Matti Lehtinen

Journal

The Lancet Oncology

Published

November 9, 2011

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Oncology

Epidemiology

Immunology

Medicine

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(11)70287-x

License

Unknown License